# Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

> **NCT03856658** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Corewell Health West** · enrollment: 14 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Liver Metastases

## Interventions

- **DRUG:** Floxuridine (FUDR)
- **DEVICE:** Hepatic Artery Infusion Pump
- **DRUG:** Heparinized Saline

## Key facts

- **NCT ID:** NCT03856658
- **Lead sponsor:** Corewell Health West
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-05
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856658, "Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03856658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*